Skip to content
Saturday 15 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Friday 30 July 2021 6:15 pm  |  Updated:  Friday 30 July 2021 6:27 pm

Sage advisers: Protection given from Covid vaccine ‘highly likely’ to wane over time

By: Amy O'Brien

Add as a preferred source on Google
Germany's Euthanasia Association has announced it will not assist unvaccinated patients with ending their lives.
Germany's Euthanasia Association has announced it will not assist unvaccinated patients with ending their lives.

Vaccine campaigns will likely have to continue for many years as the Covid immunity induced by the shots is ‘highly likely to wane over time’, according to scientific advisers to the government.

“It is highly likely that vaccine induced immunity to SARS-CoV-2 infection, and potentially
severe disease (but probably to a lesser extent) will wane over time,” the scientists said in a report summary for the government’s Scientific Advisory Group for Emergencies (SAGE).

Compromised immunity would most likely be first detected among vulnerable groups in the population, the scientists said, manifesting in hospitalisations due to infection.

“It is therefore likely that there will be vaccination campaigns against SARS-CoV-2 for many years to come, but currently we do not know what will be the optimal required frequency for re-vaccination to protect the vulnerable from COVID disease,” the summary continued.

In the UK, groups of the population have been vaccinated with three main vaccines since the rollout began in December 2020: AstraZeneca, Pfizer/BioNTech, and Moderna.

Amongst adults under 30, who were last to be offered the vaccine, the main vaccine currently being administered is Pfizer, due to a rare blood clot risk in younger receptors of the AstraZeneca jab.

It comes as Pfizer published notes in its second-quarter earnings report about a study of 45,000 people worldwide, which has not yet been peer-reviewed, that suggested a gradual “declining trend in vaccine efficacy” over the six months after two doses of its vaccine.

Echoing the SAGE adviser’s projections, the Pfizer study showed that the vaccine continued to offer strong protection against hospitalisation and more serious manifestations of the disease after six months, but overall protection appeared to weaken.

The SAGE advisers also said that immunity endurance may differ, dependent on the vaccine administered.

“Different vaccines may induce different sorts of immunity, which may have different duration. Absolute correlates of protection are yet to be determined, but the only ready measure that can be used at scale is of serum antibody,” the report said.

The scientists’ findings will boost the argument for booster shots over time as new variants emerge, a month after researchers at Oxford University found that a third “booster” shot of the AstraZeneca vaccine gave the best protection against the virus.

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • AstraZeneca
  • Coronavirus
  • Vaccine

Trending Articles

  • Revolut takes flight with launch of new airport lounges

  • Grandparents fund university degrees to avoid inheritance tax net

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • As It Happened: Stocks dip as oil’s ‘slowing demand’ in focus; Iran threatens to extend war

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Promega Achieves 100% Renewable Electricity Across Global Operations

    Business Wire
  • Where are Andy Burnham’s economic advisers?

    Politics
    Andy Burnham and John Healey at Number 10 North, both wearing suits and ties, with a microphone in the foreground.
  • Sage accelerates AI expansion as revenue grows

    Tech
    Newcastle-based Sage began has kicked off a £400m share buyback.
  • I was on the Goodyear blimp above London – here’s what it was like

    Life&Style
    Goodyear blimp hovering prominently in the sky against a clear backdrop, capturing attention with its iconic branding.
  • London-listed healthcare services firm hit by cyberattack

    Markets
    Assura has been the subject of a ferocious bidding war for nearly six months
  • 4chan ridicules Ofcom again as watchdog chases unpaid £520k fine

    Tech
    Ofcom fines 4chan in regulatory action, highlighting platforms compliance issues and internet governance challenges.
  • Prothena to Report Second Quarter 2026 Financial Results on August 6

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook